LLY
Eli Lilly and Company
NYSE · Healthcare · Drug Manufacturers - General · US
$1,143.84
−1.36%Aug 4, 2026, 12:45 UTC
Amplia Therapeutics entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to evaluate narmafotinib combined with olomorasib in non-small cell lung cancer.
Jul 30, 2026, 12:58 UTC
Eli Lilly and Resilience jointly invest $750 million to expand pharmaceutical manufacturing capacity in the United States.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 8, 2026, 07:55 UTC
Eli Lilly acquired Centessa Pharmaceuticals for $7.8 billion.
Source:Jun 30, 2026, 08:30 UTC
The Trump administration negotiated a monthly $245 price for GLP-1 drugs in Medicare and Medicaid with Eli Lilly and Novo Nordisk, contingent on private Medicare insurers covering the drugs for all uses with a $50 copay.
Source:Jun 30, 2026, 04:00 UTC
Innovent Biologics and Eli Lilly entered into a distribution and promotion agreement for Verzenios (abemaciclib) in mainland China.
Jun 29, 2026, 18:53 UTC
The FDA selected Eli Lilly and Regeneron among the first seven companies for its PreCheck Pilot Program to speed review of new manufacturing facilities.
Source:Jun 28, 2026, 20:30 UTC
Eli Lilly expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027.
Source:Jun 26, 2026, 11:16 UTC
Eli Lilly's Jaypirca (pirtobrutinib) received a positive opinion from the CHMP recommending approval in the European Union for adults with chronic lymphocytic leukemia across all lines of therapy.
Jun 26, 2026, 08:23 UTC
Eli Lilly launched The Memory Radio Station, a travelling public radio station and exhibition, across Europe to raise awareness of Alzheimer's disease early symptoms.
Jun 25, 2026, 11:00 UTC
Eli Lilly announced the acquisition of Kelonia Therapeutics, a developer of gene therapies for cancer treatment.
Source:Jun 25, 2026, 05:00 UTC
Eli Lilly launched its own data center with 1,016 advanced Blackwell computer chips from Nvidia as part of a push into AI for drug discovery.
Source:Jun 24, 2026, 20:01 UTC
Eli Lilly invested $40 million in Absci for equity, leading a $50 million funding round.
Source:Jun 24, 2026, 12:45 UTC
Eli Lilly completed its acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders.
Source:Jun 24, 2026, 01:38 UTC
Abbisko Therapeutics entered into a strategic research collaboration and license agreement with Eli Lilly.
Source:Jun 23, 2026, 13:00 UTC
NVIDIA announced the BioNeMo Agent Toolkit, a set of tools for agents to accelerate scientific discovery.
Jun 23, 2026, 04:55 UTC
Eli Lilly plans to launch a data center with 1,016 Blackwell chips in 2025.
Source:Jun 19, 2026, 08:07 UTC
Amgen India appointed Anjali Rao as executive director of human resources.
Source:Jun 18, 2026, 19:56 UTC
Eli Lilly has begun eliminating mandated 340B drug discounts to dozens of hospitals that failed to provide comprehensive claims data.
Source:Jun 9, 2026, 22:18 UTC
The FDA approved Eli Lilly's EBGLYSS for a maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis.
Source:Jun 9, 2026, 13:35 UTC
AstraZeneca reported encouraging mid-stage trial results for its experimental weight-loss pill elecoglipron, showing 11.8% weight loss after 36 weeks.
Jun 9, 2026, 08:00 UTC
Convatec and the Lilly Foundation committed approximately $5 million to Partners In Health to improve care for non-communicable diseases and chronic conditions.
Jun 8, 2026, 18:30 UTC
Eli Lilly announced detailed results from three Phase 3 trials of its oral GLP-1 drug Foundayo (orforglipron) in adults with type 2 diabetes.
Jun 4, 2026, 12:25 UTC
Eli Lilly reduces its planned investment in Germany from €2.3 billion to approximately half that amount.
Jun 2, 2026, 21:43 UTC
Cigna drops coverage of GLP-1 obesity drugs for its own employees effective July 1.
Source:Jun 2, 2026, 17:00 UTC
NewLimit raised $435 million in Series C funding led by Founders Fund, with participation from Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross.
Source:Jun 1, 2026, 22:00 UTC
Eli Lilly warned over 1,000 hospitals that they must submit comprehensive claims data within five days or lose their 340B drug discounts.
Source:May 31, 2026, 12:01 UTC
Eli Lilly announced Phase 3 LIBRETTO-432 clinical trial results for Retevmo (selpercatinib) as adjuvant therapy for early-stage RET fusion-positive lung cancer, showing an 83% reduction in risk of disease recurrence or death.
Source:
Page 1Next →